Literature DB >> 11169158

The phagocytosis of rod outer segments is inhibited by selected drugs in retinal pigment epithelial cell cultures.

M Mannerström1, H Mäenpää, T Toimela, L Salminen, H Tähti.   

Abstract

The effects of tamoxifen, toremifene and chloroquine on the phagocytosis of rod outer segments by retinal pigment epithelium were evaluated in human retinal pigment epithelial cell line D407 and pig retinal pigment epithelial cell culture. Retinal pigment epithelial cells were exposed to different concentrations of tamoxifen (1-20 microM), toremifene (1-20 microM) and chloroquine (1-1000 microM), and challenged with FITC-labeled rod outer segments for 24 hr. The phagocytized (bound and ingested) rod outer segments were measured fluorometrically, and the effect of the drugs on the phagocytosis was determined. The cytotoxicity of the drugs was evaluated by measuring their effects on mitochondrial enzyme activities (WST-1-test). The results showed that the test compounds inhibited the phagocytosis of rod outer segments in both D407 and pig retinal pigment epithelial cells. The phagocytic activity was more sensitive to tamoxifen (EC(50) 7.2 microM for D407 cells and 3.6 microM for pig retinal pigment epithelial cells) and toremifene (EC(50) 6.2 microM and 3.1 microM respectively) than to chloroquine (EC(50) 77.2 microM for D407 cells). The inhibition of rod outer segment phagocytosis in both cell cultures started at lower dose levels of test compounds than the cytotoxicity indicated by the WST-1-test. The experiments were carried out both in serum-free medium and serum-containing medium. Serum seemed to be a critical factor in the medium and caused difficulties in the interpretation of the results.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11169158     DOI: 10.1034/j.1600-0773.2001.088001027.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  7 in total

Review 1.  Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation.

Authors:  A D Garg; E Romano; N Rufo; P Agostinis
Journal:  Cell Death Differ       Date:  2016-02-19       Impact factor: 15.828

2.  FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial.

Authors:  Akosua A Nti; Leona W Serrano; Harpal S Sandhu; Katherine E Uyhazi; Ilaina D Edelstein; Elaine J Zhou; Scott Bowman; Delu Song; Tara C Gangadhar; Lynn M Schuchter; Sheryl Mitnick; Alexander Huang; Charles W Nichols; Ravi K Amaravadi; Benjamin J Kim; Tomas S Aleman
Journal:  Retina       Date:  2019-03       Impact factor: 4.256

3.  Cell viability effects of triamcinolone acetonide and preservative vehicle formulations.

Authors:  S Shaikh; S Ho; L A Engelmann; S W Klemann
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

4.  Toxicity of selected cationic drugs in retinoblastomal cultures and in cocultures of retinoblastomal and retinal pigment epithelial cell lines.

Authors:  Hanna Mäenpää; Tarja Toimela; Marika Mannerström; Pirjo Saransaari; Hanna Tähti
Journal:  Neurochem Res       Date:  2004-01       Impact factor: 3.996

Review 5.  Ocular side effects of biological agents in oncology: what should the clinician be aware of?

Authors:  Tobias Hager; B Seitz
Journal:  Onco Targets Ther       Date:  2013-12-24       Impact factor: 4.147

6.  The contribution of lysosomotropism to autophagy perturbation.

Authors:  Roshan Ashoor; Rolla Yafawi; Bart Jessen; Shuyan Lu
Journal:  PLoS One       Date:  2013-11-22       Impact factor: 3.240

7.  Improvements in visual acuity and macular morphology following cessation of anti-estrogen drugs in a patient with anti-estrogen maculopathy resembling macular telangiectasia type 2: a pathogenic hypothesis.

Authors:  Akihiro Shinkai; Wataru Saito; Yuki Hashimoto; Susumu Ishida
Journal:  BMC Ophthalmol       Date:  2019-12-30       Impact factor: 2.209

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.